Leading developer of allogeneic cellular medicines Mesoblast Limited (ASX: MSB) has struck a deal with Lonza for commercial manufacture of Mesoblast’s lead allogeneic (off-the-shelf) cell therapy product candidate, remestemcel-L for pediatric steroid-refractory acute graft versus host disease (aGVHD).
- The agreement between Mesoblast and Lonza will facilitate inventory build ahead of the planned United States (US) market launch of remestemcel-L;
- Mesoblast expects to complete filing of the rolling Biologics License Application (BLA) submission to the US Food and Drug Administration (FDA) by the end 2019;
By AEST 1:18 PM, MSB’s stock was trading at $1.845, up by 3.361% relative to previous close.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.